By Simon Hayes
•
April 3, 2023
Business, indeed life, has always been Darwinian, and InsurTech is no different. Up until recently, InsurTech was on a roll, but failed floats by big fish InsurTechs like Lemonade have put pay to that. Today, the focus and fear of ‘full stack’ disruption from InsurTechs seems to be largely over, for now at least. The barriers to entry, such as capital requirements, regulation, and the cost of building a brand and presence in competitive markets, are just too high. The shift now is towards the long overdue digital transformation of our industry and making use of its most precious resource: data. If we look back, 2016 to 2019 was filled with ‘big fish’ – well-funded InsurTechs telling our sector to brace itself for major disruption. Moving on, 2020 and 2021 seemed to focus on spectacular fundraises, IPOs, and the birth of herds of unicorns, worldwide. Heady times. In 2022, despite the headlines about plummeting post-IPO share prices and major tech layoffs, some smart InsurTechs succeeded. These firms had one thing in common: they were generally enablers, not disruptors, who utilised their technology as a force for good with incumbent market players increasingly open to new technology and fresh ideas. Last year’s reality check gave InsurTech the chance to focus on the real gems that people in our industry have been seeking – wider adoption of great technology to make the entire end-to-end process more efficient, more cost effective, and ultimately better for all stakeholders. New technology in our industry is much needed, and it is now being adopted at an unprecedented rate. Just look at the traction firms like Novidea are getting with their born-in-the-cloud insurance platform, especially following major wins with the likes of Gallagher and Hiscox. Time will tell how Silicon Valley Bank's collapse will affect the market, but hopefully the swift action by the UK Government, Bank of England, and HSBC has averted a major crisis, in the UK at least. Funding review If we look at the numbers, concerns over InsurTech funding and its future are understandable. Annual investment into InsurTech halved between 2021 and 2022, decreasing 49.5% year on year from $15.80 billion in 2021 to $7.98 billion in 2022. A huge, ‘headlining grabbing’ fall. Yet, the drop was mostly attributable to a 66.7% fall in mega-round ($100mil+) funding, from $9.76 billion in 2021 to $3.25 billion in 2021, down $6.51 billion. There was an even bigger 89.7% fall in mega-round funding from $1.48 billion in Q3 to $153 million in Q4. This is perhaps not surprising when you look at how mega-deals, like Lemonade’s, have performed when they went from major funding to the next stage with their IPOs. Not all bad news Despite the headlines, it is not all doom and gloom. If we strip out these mega-rounds, InsurTech funding in fact only dropped from $6.04 billion to $4.73 billion or 21.6%. Further, early-stage InsurTech funding only fell 7.9% year on year, from $2.15 billion in 2022 to $1.98 billion in 2021; much less dramatic than the headlines suggest. At the same time, global InsurTech deals moved from 564 in 2021 to 521 in 2022. Despite this modest fall, last year was a truly global and active year for InsurTech investing with 1,528 international investors participating in these deals, from over 60 countries. The enablers are set to win The difference now is that there is much more emphasis being placed on early-stage InsurTechs. These smaller-fish firms, with smart, agile tech and people, are adding value to our industry, not disrupting it. Firms like Supercede, Previsico, MIS, and Reask, as well as more established players like Novidea and Socotra, are great examples of this. Industry insiders clearly know their stuff, and testament to the above is the fact that 70% of corporate InsurTech investments from (re)insurers in Q4 were early stage. This shift to earlier-stage funding does not mean it’s going to be plain sailing for these InsurTechs. Valuations will be down, on those of the heady days of 2021, and i nvestors will probe harder as they look for quality, delving deeper into firms’ business models and teams, seeking not just traction, but a clear vision for profitable growth. Despite this, what’s clear is that the InsurTech space remains remarkably robust overall. My view is that it will not be the biggest, strongest or fastest InsurTechs that win, but those most adaptive to change, and those that deliver what the really market wants and needs. The best InsurTechs who are transforming our industry will gain the funding they need, along with revenue, to not only survive but thrive and swim against the tide to create true change. Darwin would be proud. Note: Funding figures source: Gallagher Re